Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Simple blood test could be developed to diagnose Alzheimer's disease, say UCLA researchers

Simple blood test could be developed to diagnose Alzheimer's disease, say UCLA researchers

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Gene therapy transforms life for men with severe form of hemophilia B

Gene therapy transforms life for men with severe form of hemophilia B

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Dynamic nuclear polarization: an interview with Professor Robert Griffin, Massachusetts Institute of Technology

Dynamic nuclear polarization: an interview with Professor Robert Griffin, Massachusetts Institute of Technology

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Research findings could lead to new approach to Alzheimer’s prevention

Research findings could lead to new approach to Alzheimer’s prevention

Drugs that boost protein's production in neurons could help ward off Alzheimer's disease

Drugs that boost protein's production in neurons could help ward off Alzheimer's disease

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes

Royal Free London NHS Foundation Trust selects OpenText to manage scanned legacy case-notes